{"id":3078,"date":"2025-04-11T10:10:21","date_gmt":"2025-04-11T08:10:21","guid":{"rendered":"https:\/\/africanova.info\/?p=3078"},"modified":"2025-04-11T10:10:23","modified_gmt":"2025-04-11T08:10:23","slug":"vaccins-et-souverainete-pharmaceutique-lafrique-prend-son-destin-en-main","status":"publish","type":"post","link":"https:\/\/africanova.info\/?p=3078","title":{"rendered":"Vaccins et souverainet\u00e9 pharmaceutique \u2013 L\u2019Afrique prend son destin en main"},"content":{"rendered":"<p>La pand\u00e9mie de COVID-19 a r\u00e9v\u00e9l\u00e9 la vuln\u00e9rabilit\u00e9 de l\u2019Afrique en mati\u00e8re de sant\u00e9 :&nbsp;<strong>moins de 1 % des vaccins produits globalement<\/strong>, d\u00e9pendance aux importations, et in\u00e9galit\u00e9s d\u2019acc\u00e8s criantes. En 2025, le continent riposte en acc\u00e9l\u00e9rant sa qu\u00eate de souverainet\u00e9 pharmaceutique, avec des projets ambitieux mais confront\u00e9s \u00e0 des d\u00e9fis structurels et g\u00e9opolitiques.<\/p><p><strong>Initiatives continentales : de la d\u00e9pendance \u00e0 l\u2019autonomie<\/strong><br>L\u2019Union africaine a lanc\u00e9 en 2024 le&nbsp;<strong>Partenariat pour la Fabrication de Vaccins en Afrique<\/strong>&nbsp;(PAVM), visant \u00e0 produire&nbsp;<strong>60 % des vaccins du continent d\u2019ici 2040<\/strong>. Des hubs r\u00e9gionaux \u00e9mergent :<\/p><ul class=\"wp-block-list\"><li><strong>Afrique du Sud<\/strong>\u00a0: Le Biovac Institute, en partenariat avec Pfizer et Moderna, produit d\u00e9sormais des vaccins ARNm contre la COVID-19 et la tuberculose.<\/li><\/ul><ul class=\"wp-block-list\"><li><strong>S\u00e9n\u00e9gal<\/strong>\u00a0: L\u2019Institut Pasteur de Dakar modernise ses lignes de production pour fabriquer\u00a0<strong>300 millions de doses annuelles<\/strong>\u00a0de vaccins contre la fi\u00e8vre jaune et la rougeole.<\/li><\/ul><ul class=\"wp-block-list\"><li><strong>Rwanda<\/strong>\u00a0: Construction d\u2019une usine BioNTech, sp\u00e9cialis\u00e9e dans les vaccins anti-paludisme, avec un investissement de\u00a0<strong>150 millions de dollars<\/strong>.<\/li><\/ul><p>Ces projets s\u2019appuient sur des financements innovants, comme les&nbsp;<strong>obligations pand\u00e9miques<\/strong>&nbsp;\u00e9mises par la BAD (Banque Africaine de D\u00e9veloppement), et des partenariats Sud-Sud (Inde, Br\u00e9sil) pour le transfert de technologies.<\/p><p><strong>D\u00e9fis persistants : financements, comp\u00e9tences, r\u00e9glementation<\/strong><br>Malgr\u00e9 les progr\u00e8s, l\u2019Afrique peine \u00e0 combler son&nbsp;<strong>d\u00e9ficit de 11 milliards de dollars<\/strong>&nbsp;pour atteindre les objectifs du PAVM. Les obstacles incluent :<\/p><ul class=\"wp-block-list\"><li><strong>P\u00e9nurie de main-d\u2019\u0153uvre qualifi\u00e9e<\/strong>\u00a0: Seulement\u00a0<strong>5 % des chercheurs pharmaceutiques mondiaux<\/strong>\u00a0sont bas\u00e9s en Afrique.<\/li><\/ul><ul class=\"wp-block-list\"><li><strong>Fragmentation r\u00e9glementaire<\/strong>\u00a0: Des normes disparates entre pays retardent l\u2019homologation des m\u00e9dicaments.<\/li><\/ul><ul class=\"wp-block-list\"><li><strong>D\u00e9pendance aux mati\u00e8res premi\u00e8res<\/strong>\u00a0: 90 % des principes actifs sont encore import\u00e9s d\u2019Asie.<\/li><\/ul><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"908\" height=\"510\" src=\"https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/phpi5jLcZ.jpg\" alt=\"\" class=\"wp-image-3080\" srcset=\"https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/phpi5jLcZ.jpg 908w, https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/phpi5jLcZ-300x169.jpg 300w, https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/phpi5jLcZ-768x431.jpg 768w, https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/phpi5jLcZ-585x329.jpg 585w, https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/phpi5jLcZ-600x337.jpg 600w\" sizes=\"(max-width: 908px) 100vw, 908px\" \/><\/figure><p><strong>Solutions innovantes et r\u00e9silience communautaire<\/strong><br>Pour surmonter ces barri\u00e8res, des approches disruptives \u00e9mergent :<\/p><ul class=\"wp-block-list\"><li><strong>R\u00e9seaux de micro-usines<\/strong>\u00a0: Des unit\u00e9s mobiles de production de vaccins, d\u00e9velopp\u00e9es par la start-up k\u00e9nyane\u00a0<strong>VaxaTech<\/strong>, ciblent les zones rurales.<\/li><\/ul><ul class=\"wp-block-list\"><li><strong>Blockchain pour la tra\u00e7abilit\u00e9<\/strong>\u00a0: La plateforme\u00a0<strong>MediChain<\/strong>, utilis\u00e9e au Ghana et au Nigeria, s\u00e9curise la distribution des m\u00e9dicaments contre les contrefa\u00e7ons.<\/li><\/ul><ul class=\"wp-block-list\"><li><strong>M\u00e9decine traditionnelle valid\u00e9e<\/strong>\u00a0: L\u2019Afrique du Sud et le Madagascar int\u00e8grent des phytom\u00e9dicaments (comme l\u2019<strong>Artemisia<\/strong>\u00a0contre le paludisme) dans leurs protocoles nationaux.<\/li><\/ul><p><strong>Coop\u00e9ration internationale : atout ou pi\u00e8ge ?<\/strong><br>Les partenariats avec l\u2019OMS, Gavi et les labos occidentaux restent essentiels, mais suscitent des d\u00e9bats. Les accords de licence obligatoire, comme celui n\u00e9goci\u00e9 par l\u2019Afrique du Sud pour produire des g\u00e9n\u00e9riques d\u2019antir\u00e9troviraux, montrent la voie. Cependant, les clauses restrictives des contrats avec Pfizer ou Moderna rappellent les risques de d\u00e9pendance technologique.<\/p><p><strong>Perspectives : vers un syst\u00e8me de sant\u00e9 int\u00e9gr\u00e9<\/strong><br>La souverainet\u00e9 pharmaceutique ne se r\u00e9sume pas aux vaccins. Elle implique :<\/p><ol start=\"1\" class=\"wp-block-list\"><li><strong>Renforcer les syst\u00e8mes de sant\u00e9 primaire<\/strong>, via des initiatives comme\u00a0<strong>Smart Health Africa<\/strong>\u00a0(drones pour acheminer des m\u00e9dicaments).<\/li><\/ol><ol start=\"2\" class=\"wp-block-list\"><li><strong>Investir dans la R&amp;D<\/strong>\u00a0locale, en s\u2019appuyant sur des universit\u00e9s (Universit\u00e9 du Cap, Universit\u00e9 Cheikh Anta Diop).<\/li><\/ol><ol start=\"3\" class=\"wp-block-list\"><li><strong>Harmoniser les politiques sanitaires<\/strong>\u00a0via l\u2019Agence Africaine du M\u00e9dicament (AMA), op\u00e9rationnelle depuis 2024.<\/li><\/ol><p>En conclusion, l\u2019Afrique transforme sa vuln\u00e9rabilit\u00e9 en opportunit\u00e9. En combinant innovations locales, coop\u00e9ration r\u00e9gionale et partenariats \u00e9quitables, le continent b\u00e2tit un \u00e9cosyst\u00e8me pharmaceutique r\u00e9silient \u2013 cl\u00e9 pour sa s\u00e9curit\u00e9 sanitaire et son ind\u00e9pendance strat\u00e9gique.<\/p><div class=\"gsp_post_data\" data-post_type=\"post\" data-cat=\"sante-publique\" data-modified=\"120\" data-title=\"Vaccins et souverainet\u00e9 pharmaceutique \u2013 L\u2019Afrique prend son destin en main\" data-home=\"https:\/\/africanova.info\"><\/div>","protected":false},"excerpt":{"rendered":"<p>La pand\u00e9mie de COVID-19 a r\u00e9v\u00e9l\u00e9 la vuln\u00e9rabilit\u00e9 de l\u2019Afrique en mati\u00e8re de sant\u00e9 :&nbsp;moins de 1 % des vaccins produits globalement, d\u00e9pendance aux importations, et in\u00e9galit\u00e9s d\u2019acc\u00e8s criantes. En&hellip;<\/p>\n","protected":false},"author":1,"featured_media":3079,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_lmt_disableupdate":"","_lmt_disable":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[274],"tags":[],"class_list":["post-3078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sante-publique"],"jetpack_featured_media_url":"https:\/\/africanova.info\/wp-content\/uploads\/2025\/04\/image1440x560cropped.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/posts\/3078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/africanova.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3078"}],"version-history":[{"count":1,"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/posts\/3078\/revisions"}],"predecessor-version":[{"id":3081,"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/posts\/3078\/revisions\/3081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/africanova.info\/index.php?rest_route=\/wp\/v2\/media\/3079"}],"wp:attachment":[{"href":"https:\/\/africanova.info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/africanova.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/africanova.info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}